The FDA standardized bioequivalence administration protocols across product-specific guidances for generic chewable tablets. The regulatory review aims to align local administration approaches with harmonized international testing standards. For developers and quality teams, harmonization can reduce variability in how trials are executed for chewable oral solids and may simplify dossier preparation across product lines. The update is relevant to generic manufacturers and contract research organizations running pivotal bioavailability and bioequivalence studies. Even when formulations are equivalent on paper, administration protocol consistency affects pharmacokinetic readouts, so the FDA’s focus signals an effort to tighten regulatory repeatability.